Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24457828 | 0.85 | ACLY (0.44) | ACLYABL1SERPINH1SLC6A4SLC6A3 | |
| SCHEMBL6272999 | 0.84 | GAA (0.39) | ACLYABL1MAPTCA1CA2 | |
| SCHEMBL21999818 | 0.83 | ACLY (0.53) | ACLYABL1F2PRSS1PRSS2 | |
| SCHEMBL3531626 | 0.80 | AKR1C2 (0.58) | ACLYMAPTCA1CA2CA9 | |
| SCHEMBL17078006 | 0.79 | TRPV4 (0.56) | ACLYABL1SLC6A4SLC6A3TRPV4 | |
| SCHEMBL5452555 | 0.79 | ABL1 (0.58) | ACLYABL1MAPTSLC6A4SLC6A3 | |
| SCHEMBL1549467 | 0.78 | ABL1 (0.62) | ACLYABL1SERPINH1MITFMAPT | |
| SCHEMBL423691 | 0.78 | AKR1C4 (0.60) | ACLYABL1SERPINH1SLC6A4SLC6A3 | |
| SCHEMBL855750 | 0.78 | LMNA (0.52) | ACLYABL1SERPINH1MITFMAPT | |
| SCHEMBL12478545 | 0.76 | ABL1 (0.46) | ACLYABL1SERPINH1MITFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| CN-100396677-C | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2008-06-25 | — | — | CN | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| CN-1675197-A | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885ABL1 2859/4885F2 3257/4885 |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | ACLY 1773/4885ABL1 523/4885F2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.